CN114174294B - 用于抑制janus激酶1的新化合物 - Google Patents

用于抑制janus激酶1的新化合物 Download PDF

Info

Publication number
CN114174294B
CN114174294B CN202080054241.8A CN202080054241A CN114174294B CN 114174294 B CN114174294 B CN 114174294B CN 202080054241 A CN202080054241 A CN 202080054241A CN 114174294 B CN114174294 B CN 114174294B
Authority
CN
China
Prior art keywords
pyridin
pyrazol
imidazo
trifluoro
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080054241.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN114174294A (zh
Inventor
桑托什·库马尔·拉伊
马哈德夫·班加
萨齐德·阿里
希曼苏·拉伊
阿莫尔·潘杜朗·冈哈尔
拉凯什·伊斯瓦尔·帕蒂尔
斯里尼瓦萨·雷迪·巴普兰
阿尼尔·库马尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mankind Pharma Ltd
Original Assignee
Mankind Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mankind Pharma Ltd filed Critical Mankind Pharma Ltd
Publication of CN114174294A publication Critical patent/CN114174294A/zh
Application granted granted Critical
Publication of CN114174294B publication Critical patent/CN114174294B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202080054241.8A 2019-05-28 2020-05-26 用于抑制janus激酶1的新化合物 Active CN114174294B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201911021098 2019-05-28
IN201911021098 2019-05-28
PCT/IN2020/050471 WO2020240586A1 (en) 2019-05-28 2020-05-26 Novel compounds for inhibition of janus kinase 1

Publications (2)

Publication Number Publication Date
CN114174294A CN114174294A (zh) 2022-03-11
CN114174294B true CN114174294B (zh) 2024-10-25

Family

ID=73553608

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080054241.8A Active CN114174294B (zh) 2019-05-28 2020-05-26 用于抑制janus激酶1的新化合物

Country Status (11)

Country Link
US (1) US12516056B2 (https=)
EP (1) EP3976612A4 (https=)
JP (1) JP7592029B2 (https=)
CN (1) CN114174294B (https=)
AU (1) AU2020284742B2 (https=)
BR (1) BR112021023635A2 (https=)
CA (1) CA3141571A1 (https=)
MX (1) MX2021014361A (https=)
TW (1) TWI839524B (https=)
WO (1) WO2020240586A1 (https=)
ZA (1) ZA202109183B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023526521A (ja) * 2020-05-21 2023-06-21 ステムシナジー セラピューティクス， インク． Ｎｏｔｃｈ阻害剤及びそれらの使用
WO2022166796A1 (zh) * 2021-02-05 2022-08-11 上海齐鲁制药研究中心有限公司 嘧啶或吡啶并杂环类腺苷受体抑制剂及其制备方法和用途
PE20250019A1 (es) * 2021-05-06 2025-01-07 Exscientia Ai Ltd MODULADORES DE PKC-theta
WO2022234298A1 (en) * 2021-05-06 2022-11-10 Exscientia Ai Limited Pkc-theta modulators
EP4452944A1 (en) * 2021-12-22 2024-10-30 Icagen, LLC Cyclopropyl compounds
CN117050074B (zh) * 2022-05-05 2025-08-12 中国药科大学 一类吡啶联咪唑并吡啶化合物及其制备方法与用途

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007040438A2 (en) * 2005-10-03 2007-04-12 Astrazeneca Ab Novel imidazo [4,5 -b] pyridine derivatives as inhibitors of glycogen synthase kinase 3 for use in the treatment of dementia and neurodegenerative disorders
WO2010003133A2 (en) * 2008-07-03 2010-01-07 Exelixis Inc. Cdk modulators
WO2013116291A1 (en) * 2012-01-30 2013-08-08 Cephalon, Inc. Imidazo [4, 5 - b] pyridine derivatives as alk and jak modulators for the treatment of proliferative disorders
CN104024243A (zh) * 2011-12-28 2014-09-03 韩美药品株式会社 作为酪氨酸激酶抑制剂的新咪唑并吡啶衍生物
CN106146504A (zh) * 2015-04-17 2016-11-23 上海汇伦生命科技有限公司 一种杂环并咪唑类化合物、其药物组合物及其制备方法和用途
WO2017097224A1 (zh) * 2015-12-11 2017-06-15 四川科伦博泰生物医药股份有限公司 氮杂环丁烷衍生物、其制备方法及用途
WO2018035080A1 (en) * 2016-08-16 2018-02-22 Merck Patent Gmbh 2-oxo-imidazopyridines as reversible btk inhibitors and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5002851B2 (ja) * 2005-01-20 2012-08-15 独立行政法人理化学研究所 イミダゾピリジン誘導体
US7534796B2 (en) 2005-02-18 2009-05-19 Wyeth Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
SG10202003901UA (en) * 2005-12-13 2020-05-28 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
EP2244711A4 (en) * 2008-02-04 2011-08-24 Cytokinetics Inc CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS
WO2010036316A1 (en) 2008-09-24 2010-04-01 Yangbo Feng Urea and carbamate compounds and analogs as kinase inhibitors
FI124118B (fi) * 2011-06-13 2014-03-31 Reijo Uolevi Hautalahti Aurinkoenergian avulla sähköä ja lämpöä tuottava voimala
CN104140426B (zh) * 2013-05-07 2017-02-01 上海汇伦生命科技有限公司 嘧啶并咪唑类化合物、其药物组合物及其制备方法和用途
US10253023B2 (en) 2014-10-06 2019-04-09 Merck Patent Gmbh Heteroaryl compounds as BTK inhibitors and uses thereof
CN105837572B (zh) 2015-02-02 2019-04-19 四川大学 N-取代苯基酰胺衍生物及其制备方法和用途
GB201717260D0 (en) 2017-10-20 2017-12-06 Galapagos Nv Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders
CN113508114B (zh) * 2019-02-27 2024-03-26 四川科伦博泰生物医药股份有限公司 以氮杂环丁烷衍生物为活性成分的口服药物组合物、其制备方法及用途

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007040438A2 (en) * 2005-10-03 2007-04-12 Astrazeneca Ab Novel imidazo [4,5 -b] pyridine derivatives as inhibitors of glycogen synthase kinase 3 for use in the treatment of dementia and neurodegenerative disorders
WO2010003133A2 (en) * 2008-07-03 2010-01-07 Exelixis Inc. Cdk modulators
CN104024243A (zh) * 2011-12-28 2014-09-03 韩美药品株式会社 作为酪氨酸激酶抑制剂的新咪唑并吡啶衍生物
WO2013116291A1 (en) * 2012-01-30 2013-08-08 Cephalon, Inc. Imidazo [4, 5 - b] pyridine derivatives as alk and jak modulators for the treatment of proliferative disorders
CN106146504A (zh) * 2015-04-17 2016-11-23 上海汇伦生命科技有限公司 一种杂环并咪唑类化合物、其药物组合物及其制备方法和用途
WO2017097224A1 (zh) * 2015-12-11 2017-06-15 四川科伦博泰生物医药股份有限公司 氮杂环丁烷衍生物、其制备方法及用途
WO2018035080A1 (en) * 2016-08-16 2018-02-22 Merck Patent Gmbh 2-oxo-imidazopyridines as reversible btk inhibitors and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Binding to an Unusual Inactive Kinase Conformation by Highly Selective Inhibitors of Inositol-Requiring Enzyme 1αKinaseEndoribonuclease;Giampiero Colombano 等;Journal of Medicinal Chemistry;第62卷;Supporting Information S15页 *
Imidazopyridine-Based Inhibitors of Glycogen Synthase Kinase 3: Synthesis and Evaluation of Amide Isostere Replacements of the Carboxamide Scaffold;Ulrika Yngve 等;CHEMISTRY & BIODIVERSITY;第9卷;第2445页 *
Imidazopyridines as selective CYP3A4 inhibitors;Xinyi Song 等;Bioorganic & Medicinal Chemistry Letters;第22卷;第1612页 *

Also Published As

Publication number Publication date
TW202110838A (zh) 2021-03-16
JP7592029B2 (ja) 2024-11-29
CA3141571A1 (en) 2020-12-03
ZA202109183B (en) 2022-08-31
EP3976612A4 (en) 2023-04-26
US20220235046A1 (en) 2022-07-28
CN114174294A (zh) 2022-03-11
EP3976612A1 (en) 2022-04-06
MX2021014361A (es) 2022-04-06
AU2020284742B2 (en) 2026-03-05
US12516056B2 (en) 2026-01-06
BR112021023635A2 (pt) 2022-02-01
JP2022534510A (ja) 2022-08-01
AU2020284742A1 (en) 2022-02-03
WO2020240586A1 (en) 2020-12-03
TWI839524B (zh) 2024-04-21

Similar Documents

Publication Publication Date Title
CN114174294B (zh) 用于抑制janus激酶1的新化合物
JP7654643B2 (ja) ホスホジエステラーゼ阻害剤および使用
RU2269527C2 (ru) Производные пиридопиримидинов, способы их получения и фармацевтическая композиция на их основе
JP4860609B2 (ja) 縮合ヘテロ環キナーゼ阻害剤
EP2150544B1 (en) Mapk/erk kinase inhibitors
JP6239139B2 (ja) 新規化合物
US20040058930A1 (en) Thiophene-based tricyclic compounds and pharmaceutical compositions comprising same
AU2006350748A2 (en) 7-substituted purine derivatives for immunosuppression
KR20000068010A (ko) 아졸로 트리아진 및 피리미딘
JP2009542604A (ja) ４−ヘテロシクロアルキルピリミジン、それらの調製方法及び医薬としての使用
AU2011344270A1 (en) Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof
KR20110039383A (ko) ｃＭＥＴ 억제제
EA015513B1 (ru) Карбониламинопирролопиразолы в качестве эффективных ингибиторов киназ
KR20230157432A (ko) 야누스 키나아제 억제제로서 헤테로사이클릭 유도체
US9115149B2 (en) Heterocyclic compounds as inhibitors of fatty acid biosysnthesis for bacterial infections
KR20230157431A (ko) 야누스 키나아제 억제제로서 헤테로사이클릭 유도체
CN101027305A (zh) 稠合杂环型激酶抑制剂
RU2833828C2 (ru) Новые соединения для ингибирования янус-киназы 1

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant